It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Regarding the important role of α-glucosidase enzyme in the management of type 2 diabetes mellitus, the current study was established to design and synthesize aryl-quinoline-4-carbonyl hydrazone bearing different 2-methoxyphenoxyacetamide (11a–o) and the structure of all derivatives was confirmed through various techniques including IR, 1H-NMR, 13C-NMR and elemental analysis. Next, the α-glucosidase inhibitory potentials of all derivatives were evaluated, and all compounds displayed potent inhibition with IC50 values in the range of 26.0 ± 0.8–459.8 ± 1.5 µM as compared to acarbose used as control, except 11f and 11l. Additionally, in silico-induced fit docking and molecular dynamics studies were performed to further investigate the interaction, orientation, and conformation of the newly synthesized compounds over the active site of α-glucosidase.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Alborz University of Medical Sciences, CinnaGen Medical Biotechnology Research Center, Karaj, Iran (ISNI:0000 0004 4651 6731); CinnaGen Research and Production Co., Alborz, Iran
2 Tehran University of Medical Sciences, Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922)
3 Iran University of Medical Sciences, Department of Medicinal Chemistry, School of Pharmacy, Tehran, Iran (GRID:grid.411746.1) (ISNI:0000 0004 4911 7066)
4 Shiraz University of Medical Sciences, Research Center for Traditional Medicine and History of Medicine, Department of Persian Medicine, School of Medicine, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698); Shiraz University of Medical Sciences, Stem Cells Technology Research Center, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698)
5 Iran University of Science and Technology, Pharmaceutical and Heterocyclic Chemistry Research Laboratory, Department of Chemistry, Tehran, Iran (GRID:grid.411748.f) (ISNI:0000 0001 0387 0587)
6 Alborz University of Medical Sciences, Student Research Committee, Karaj, Iran (GRID:grid.411748.f) (ISNI:0000 0004 4651 6731)
7 Tehran University of Medical Sciences, Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922)
8 Tehran University of Medical Sciences, Nano Alvand Company, Avicenna Tech Park, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922)